173 related articles for article (PubMed ID: 37586773)
21. Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors.
Incorvaia L; Madonia G; Corsini LR; Cucinella A; Brando C; Gagliardo C; Santoni M; Fanale D; Inno A; Fazio I; Foti G; Galia M; Badalamenti G; Bazan V; Russo A; Gori S
Crit Rev Oncol Hematol; 2021 Jul; 163():103390. PubMed ID: 34090998
[TBL] [Abstract][Full Text] [Related]
22. Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells.
Khan MI; Czarnecka AM; Lewicki S; Helbrecht I; Brodaczewska K; Koch I; Zdanowski R; Król M; Szczylik C
PLoS One; 2016; 11(11):e0165718. PubMed ID: 27812180
[TBL] [Abstract][Full Text] [Related]
23. Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases.
Lu BY; Gupta R; Aguirre-Ducler A; Gianino N; Wyatt H; Ribeiro M; Chiang VL; Contessa JN; Adeniran AJ; Jilaveanu LB; Kluger HM; Schalper KA; Goldberg SB
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34670827
[TBL] [Abstract][Full Text] [Related]
24. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors.
Lee CT; Genega EM; Hutchinson B; Fearn PA; Kattan MW; Russo P; Reuter VE
Urol Oncol; 2003; 21(3):179-84. PubMed ID: 12810203
[TBL] [Abstract][Full Text] [Related]
25. Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.
Davidson G; Helleux A; Vano YA; Lindner V; Fattori A; Cerciat M; Elaidi RT; Verkarre V; Sun CM; Chevreau C; Bennamoun M; Lang H; Tricard T; Fridman WH; Sautes-Fridman C; Su X; Plassard D; Keime C; Thibault-Carpentier C; Barthelemy P; Oudard SM; Davidson I; Malouf GG
Cancer Res; 2023 Sep; 83(17):2952-2969. PubMed ID: 37335139
[TBL] [Abstract][Full Text] [Related]
26. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
[TBL] [Abstract][Full Text] [Related]
27. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response.
Hajiran A; Chakiryan N; Aydin AM; Zemp L; Nguyen J; Laborde JM; Chahoud J; Spiess PE; Zaman S; Falasiri S; Fournier M; Teer JK; Dhillon J; McCarthy S; Moran-Segura C; Katende EN; Sexton WJ; Koomen JM; Mulé J; Kim Y; Manley B
Clin Exp Immunol; 2021 Apr; 204(1):96-106. PubMed ID: 33346915
[TBL] [Abstract][Full Text] [Related]
28. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
[TBL] [Abstract][Full Text] [Related]
30. Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes.
Ho TH; Serie DJ; Parasramka M; Cheville JC; Bot BM; Tan W; Wang L; Joseph RW; Hilton T; Leibovich BC; Parker AS; Eckel-Passow JE
Ann Oncol; 2017 Mar; 28(3):604-610. PubMed ID: 27993815
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.
Romero JM; Aptsiauri N; Vazquez F; Cozar JM; Canton J; Cabrera T; Tallada M; Garrido F; Ruiz-Cabello F
Tissue Antigens; 2006 Oct; 68(4):303-10. PubMed ID: 17026465
[TBL] [Abstract][Full Text] [Related]
32. Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.
Schoenfeld DA; Merkin RD; Moutafi M; Martinez S; Adeniran A; Kumar D; Jilaveanu L; Hurwitz M; Rimm DL; Kluger HM
Front Oncol; 2022; 12():990367. PubMed ID: 36313654
[TBL] [Abstract][Full Text] [Related]
33. Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy.
Huntoon K; Damante M; Wang J; Olencki T; Elder JB
Curr Probl Cancer; 2022 Apr; 46(2):100805. PubMed ID: 34836657
[TBL] [Abstract][Full Text] [Related]
34. Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.
Cai C; Xu YF; Wu ZJ; Dong Q; Li MY; Olson JC; Rabinowitz YM; Wang LH; Sun Y
World J Urol; 2016 Apr; 34(4):561-7. PubMed ID: 26253654
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of single-cell RNA-seq and bulk RNA-seq revealed the heterogeneity and convergence of the immune microenvironment in renal cell carcinoma.
Lv S; Tao L; Liao H; Huang Z; Lu Y
Funct Integr Genomics; 2023 Jun; 23(2):193. PubMed ID: 37264263
[TBL] [Abstract][Full Text] [Related]
37. Global management of brain metastasis from renal cell carcinoma.
Pierrard J; Tison T; Grisay G; Seront E
Crit Rev Oncol Hematol; 2022 Mar; 171():103600. PubMed ID: 35063636
[TBL] [Abstract][Full Text] [Related]
38. Comparative analyses of the prognosis, tumor immune microenvironment, and drug treatment response between left-sided and right-sided colon cancer by integrating scRNA-seq and bulk RNA-seq data.
Cao L; Zhang S; Yao D; Ba Y; Weng Q; Yang J; Zhang H; Ren Y
Aging (Albany NY); 2023 Jul; 15(14):7098-7123. PubMed ID: 37480572
[TBL] [Abstract][Full Text] [Related]
39. Renal cell carcinoma pathology in 2021: 'new need for renal cancer immune profiling'.
Sobottka B; Lorch A; Silina K; van den Broek M; Moch H
Curr Opin Urol; 2021 May; 31(3):228-235. PubMed ID: 33742986
[TBL] [Abstract][Full Text] [Related]
40. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
